Sophia Neisinger, Bernardo Sousa Pinto, Aiste Ramanauskaite, Jean Bousquet, Karsten Weller, Martin Metz, Markus Magerl, Emek Kocatürk, Ivan Cherrez-Ojeda, Ana M. Gimenez-Arnau, Claudio Alberto S. Parisi, Sabine Altrichter, Luis Felipe Ensina, Laurence Bouillet, Riccardo Asero, Margarida Gonçalo, Carole Guillet, Krzysztof Rutkowski, Jonathan A. Bernstein, Hannah Hardin, Kiran Godse, Zenon Brzoza, Jose Ignacio Larco Sousa, Simon Francis Thomsen, Martijn van Doorn, Michihiro Hide, Young-Min Ye, Staffan Vanderse, Lāsma Lapiņa, Jonny Peter, Zuotao Zhao, Lianyi Han, Iman Nasr, Heike Rockmann-Helmbach, Jennifer Astrup Sørensen, Rabia Öztaş Kara, Natalja Kurjāne, Andrii I. Kurchenko, Igor Kaidashev, Vladyslav Tsaryk, Roman Stepanenko, Marcus Maurer
{"title":"CRUSE®-用于慢性自发性荨麻疹患者监测和管理的创新型移动应用程序","authors":"Sophia Neisinger, Bernardo Sousa Pinto, Aiste Ramanauskaite, Jean Bousquet, Karsten Weller, Martin Metz, Markus Magerl, Emek Kocatürk, Ivan Cherrez-Ojeda, Ana M. Gimenez-Arnau, Claudio Alberto S. Parisi, Sabine Altrichter, Luis Felipe Ensina, Laurence Bouillet, Riccardo Asero, Margarida Gonçalo, Carole Guillet, Krzysztof Rutkowski, Jonathan A. Bernstein, Hannah Hardin, Kiran Godse, Zenon Brzoza, Jose Ignacio Larco Sousa, Simon Francis Thomsen, Martijn van Doorn, Michihiro Hide, Young-Min Ye, Staffan Vanderse, Lāsma Lapiņa, Jonny Peter, Zuotao Zhao, Lianyi Han, Iman Nasr, Heike Rockmann-Helmbach, Jennifer Astrup Sørensen, Rabia Öztaş Kara, Natalja Kurjāne, Andrii I. Kurchenko, Igor Kaidashev, Vladyslav Tsaryk, Roman Stepanenko, Marcus Maurer","doi":"10.1002/clt2.12328","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Chronic spontaneous urticaria (CSU) is unpredictable and can severely impair patients' quality of life. Patients with CSU need a convenient, user-friendly platform to complete patient-reported outcome measures (PROMs) on their mobile devices. CRUSE<sup>®</sup>, the Chronic Urticaria Self Evaluation app, aims to address this unmet need.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>CRUSE<sup>®</sup> was developed by an international steering committee of urticaria specialists. Priorities for the app based on recent findings in CSU were defined to allow patients to track and record their symptoms and medication use over time and send photographs. The CRUSE<sup>®</sup> app collects patient data such as age, sex, disease onset, triggers, medication, and CSU characteristics that can be sent securely to physicians, providing real-time insights. Additionally, CRUSE<sup>®</sup> contains PROMs to assess disease activity and control, which are individualised to patient profiles and clinical manifestations.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>CRUSE<sup>®</sup> was launched in Germany in March 2022 and is now available for free in 17 countries. It is adapted to the local language and displays a country-specific list of available urticaria medications. English and Ukrainian versions are available worldwide. From July 2022 to June 2023, 25,710 observations were documented by 2540 users; 72.7% were females, with a mean age of 39.6 years. At baseline, 93.7% and 51.3% of users had wheals and angioedema, respectively. Second-generation antihistamines were used in 74.0% of days.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>The initial data from CRUSE<sup>®</sup> show the wide use and utility of effectively tracking patients' disease activity and control, paving the way for personalised CSU management.</p>\n </section>\n </div>","PeriodicalId":10334,"journal":{"name":"Clinical and Translational Allergy","volume":null,"pages":null},"PeriodicalIF":4.6000,"publicationDate":"2024-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/clt2.12328","citationCount":"0","resultStr":"{\"title\":\"CRUSE®—An innovative mobile application for patient monitoring and management in chronic spontaneous urticaria\",\"authors\":\"Sophia Neisinger, Bernardo Sousa Pinto, Aiste Ramanauskaite, Jean Bousquet, Karsten Weller, Martin Metz, Markus Magerl, Emek Kocatürk, Ivan Cherrez-Ojeda, Ana M. Gimenez-Arnau, Claudio Alberto S. Parisi, Sabine Altrichter, Luis Felipe Ensina, Laurence Bouillet, Riccardo Asero, Margarida Gonçalo, Carole Guillet, Krzysztof Rutkowski, Jonathan A. Bernstein, Hannah Hardin, Kiran Godse, Zenon Brzoza, Jose Ignacio Larco Sousa, Simon Francis Thomsen, Martijn van Doorn, Michihiro Hide, Young-Min Ye, Staffan Vanderse, Lāsma Lapiņa, Jonny Peter, Zuotao Zhao, Lianyi Han, Iman Nasr, Heike Rockmann-Helmbach, Jennifer Astrup Sørensen, Rabia Öztaş Kara, Natalja Kurjāne, Andrii I. Kurchenko, Igor Kaidashev, Vladyslav Tsaryk, Roman Stepanenko, Marcus Maurer\",\"doi\":\"10.1002/clt2.12328\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Background</h3>\\n \\n <p>Chronic spontaneous urticaria (CSU) is unpredictable and can severely impair patients' quality of life. Patients with CSU need a convenient, user-friendly platform to complete patient-reported outcome measures (PROMs) on their mobile devices. CRUSE<sup>®</sup>, the Chronic Urticaria Self Evaluation app, aims to address this unmet need.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Methods</h3>\\n \\n <p>CRUSE<sup>®</sup> was developed by an international steering committee of urticaria specialists. Priorities for the app based on recent findings in CSU were defined to allow patients to track and record their symptoms and medication use over time and send photographs. The CRUSE<sup>®</sup> app collects patient data such as age, sex, disease onset, triggers, medication, and CSU characteristics that can be sent securely to physicians, providing real-time insights. Additionally, CRUSE<sup>®</sup> contains PROMs to assess disease activity and control, which are individualised to patient profiles and clinical manifestations.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Results</h3>\\n \\n <p>CRUSE<sup>®</sup> was launched in Germany in March 2022 and is now available for free in 17 countries. It is adapted to the local language and displays a country-specific list of available urticaria medications. English and Ukrainian versions are available worldwide. From July 2022 to June 2023, 25,710 observations were documented by 2540 users; 72.7% were females, with a mean age of 39.6 years. At baseline, 93.7% and 51.3% of users had wheals and angioedema, respectively. Second-generation antihistamines were used in 74.0% of days.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusions</h3>\\n \\n <p>The initial data from CRUSE<sup>®</sup> show the wide use and utility of effectively tracking patients' disease activity and control, paving the way for personalised CSU management.</p>\\n </section>\\n </div>\",\"PeriodicalId\":10334,\"journal\":{\"name\":\"Clinical and Translational Allergy\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":4.6000,\"publicationDate\":\"2024-01-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1002/clt2.12328\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical and Translational Allergy\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/clt2.12328\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ALLERGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Translational Allergy","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/clt2.12328","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ALLERGY","Score":null,"Total":0}
CRUSE®—An innovative mobile application for patient monitoring and management in chronic spontaneous urticaria
Background
Chronic spontaneous urticaria (CSU) is unpredictable and can severely impair patients' quality of life. Patients with CSU need a convenient, user-friendly platform to complete patient-reported outcome measures (PROMs) on their mobile devices. CRUSE®, the Chronic Urticaria Self Evaluation app, aims to address this unmet need.
Methods
CRUSE® was developed by an international steering committee of urticaria specialists. Priorities for the app based on recent findings in CSU were defined to allow patients to track and record their symptoms and medication use over time and send photographs. The CRUSE® app collects patient data such as age, sex, disease onset, triggers, medication, and CSU characteristics that can be sent securely to physicians, providing real-time insights. Additionally, CRUSE® contains PROMs to assess disease activity and control, which are individualised to patient profiles and clinical manifestations.
Results
CRUSE® was launched in Germany in March 2022 and is now available for free in 17 countries. It is adapted to the local language and displays a country-specific list of available urticaria medications. English and Ukrainian versions are available worldwide. From July 2022 to June 2023, 25,710 observations were documented by 2540 users; 72.7% were females, with a mean age of 39.6 years. At baseline, 93.7% and 51.3% of users had wheals and angioedema, respectively. Second-generation antihistamines were used in 74.0% of days.
Conclusions
The initial data from CRUSE® show the wide use and utility of effectively tracking patients' disease activity and control, paving the way for personalised CSU management.
期刊介绍：
Clinical and Translational Allergy, one of several journals in the portfolio of the European Academy of Allergy and Clinical Immunology, provides a platform for the dissemination of allergy research and reviews, as well as EAACI position papers, task force reports and guidelines, amongst an international scientific audience.
Clinical and Translational Allergy accepts clinical and translational research in the following areas and other related topics: asthma, rhinitis, rhinosinusitis, drug hypersensitivity, allergic conjunctivitis, allergic skin diseases, atopic eczema, urticaria, angioedema, venom hypersensitivity, anaphylaxis, food allergy, immunotherapy, immune modulators and biologics, animal models of allergic disease, immune mechanisms, or any other topic related to allergic disease.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
